Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 Patients

Version 1 : Received: 10 August 2020 / Approved: 12 August 2020 / Online: 12 August 2020 (11:12:41 CEST)

How to cite: Ramírez, E.; Urroz, M.; Rodríguez Mariblanca, A.; Martín-Vega, A.; Villán, Y.; Seco, E.; Monserrat, J.; Frías, J.; Carcas, A.J.; Borobia, A.M. Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 Patients. Preprints 2020, 2020080283 (doi: 10.20944/preprints202008.0283.v1). Ramírez, E.; Urroz, M.; Rodríguez Mariblanca, A.; Martín-Vega, A.; Villán, Y.; Seco, E.; Monserrat, J.; Frías, J.; Carcas, A.J.; Borobia, A.M. Suspected Serious Adverse Drug Reactions in Hospitalized COVID-19 Patients. Preprints 2020, 2020080283 (doi: 10.20944/preprints202008.0283.v1).

Abstract

BACKGROUND: From March to April 2020, Spain was the center of the SARS-CoV-2 pandemic, particularly Madrid with approximately 30% of the cases in Spain. The aim of this study is to report the suspected serious adverse drug reactions (SADRs) in COVID-19 patients versus non-COVID-19 patients detected by the prospective pharmacovigilance program based on automatic laboratory signals (ALSs) in the hospital (PPLSH) during that period. We also compared the results with the suspected SADRs detected during the same period for 2019. METHODS: All ALSs that reflected potential SADRs (including neutropenia, pancytopenia, thrombocytopenia, anemia, eosinophilia, leukocytes in cerebrospinal fluid, hepatitis, pancreatitis, acute kidney injury, rhabdomyolysis and hyponatremia were prospectively monitored in hospitalized patients during the study periods. We analyzed the incidence and the distribution of causative drugs for the COVID-19 patients. RESULTS: The incidence rate of SADRs detected in the COVID-19 patients was 760.63 (95% CI 707.89–816.01) per 10,000 patients, 4.75-fold higher than the SADR rate for non-COVID-19 patients (160.15 per 10,000 patients,95% CI 137.09–186.80), and 5.84-fold higher than the SADR rate detected for the same period in 2019 (130.19 per 10,000 patients, 95% CI 109.53–154.36). The most frequently related drugs were tocilizumab (59.84%), dexketoprofen (13.93%), azithromycin (8.43%), lopinavir-ritonavir (7.35%), dexamethasone (7.62%), and chloroquine/hydroxychloroquine (6.91%). CONCLUSIONS: The incidence rate of SADRs detected by the PPSLH in patients with COVID-19 was 4.75-fold higher than that of the non-COVID-19 patients. Caution is recommended when using medications for COVID-19 patients, especially drugs that are hepatotoxic, myotoxic, and those that induce thromboembolic events.

Subject Areas

Adverse drug reaction; COVID-19 treatment

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.